BioVie (BIVI) vs Senti Biosciences (SNTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioVie (BIVI) has outperformed Senti Biosciences (SNTI) over the past year, losing 28.7% versus a loss of 83.5%. Over five years, SNTI leads with a -99.7% price change compared with -99.8% for BIVI. BioVie is the larger company by market cap ($12.1 million vs $9.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIVI | SNTI |
|---|---|---|
| Share price | $1.39 | $0.3144 |
| Market cap | $12.07M | $9.79M |
| 1-day change | +8.59% | -2.27% |
| YTD return | +19.83% | -69.77% |
| 1-year return | -28.72% | -83.45% |
| 5-year return | -99.76% | -99.68% |
| EPS (TTM) | $-3.05 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.79 | $2.88 |
| 52-week low | $0.82 | $0.29 |
| Distance from 52-week high | -63.32% | -89.08% |
| Analyst consensus | none | none |
| Avg. price target upside | +278.42% | +4193.89% |
| Average volume | 4.60M | 573.78K |
| Shares outstanding | 8.68M | 31.15M |
| Employees | 13 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIVI has outperformed SNTI by 54.7 percentage points over the past year.
About BioVie
BIVI stock →BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Senti Biosciences
SNTI stock →Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
BIVI vs SNTI FAQ
Which is bigger, BioVie or Senti Biosciences?
BioVie (BIVI) is larger, with a market capitalization of $12.07M compared with $9.79M for Senti Biosciences (SNTI).
Which stock has performed better over the past year, BIVI or SNTI?
BIVI returned -28.72% over the past 12 months, compared with -83.45% for SNTI (price return, excluding dividends). Past performance does not predict future results.
Are BioVie and Senti Biosciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for BioVie and Biotechnology: Biological Products (No Diagnostic Substances) for Senti Biosciences.